8.97

9.93% 0.81

After Hours: 9.27 0.30 +3.34%

Karyopharm Therapeutics Inc (KPTI)

Overview News Price History Option Chain Financials Discussions Forecast

Karyopharm Therapeutics Inc stock is traded at $8.97, with a volume of 503.24K. It is up +9.93% in the last 24 hours and up +3.58% over the past month. Karyopharm Therapeutics Inc is a commercial-stage pharmaceutical company focused on novel cancer therapies and dedicated to the discovery, development, and commercialization of drugs directed against nuclear export for the treatment of cancer and other diseases. The company conducts research focused on intracellular communication between the nucleus and cytoplasm and has developed small-molecule compounds that inhibit exportin 1 (XPO1), a nuclear export protein. It is focused on marketing XPOVIO (selinexor).

Previous Close:

$8.16

Open:

$8.3

24h Volume:

503.24K

Relative Volume:

0.56

Market Cap:

$203.29M

Revenue:

$146.07M

Net Income/Loss:

$-196.04M

P/E Ratio:

-0.5397

EPS:

-16.621

Net Cash Flow:

$-75.37M

1W Performance:

+20.08%

1M Performance:

+3.58%

6M Performance:

+61.62%

1Y Performance:

+95.42%

1-Day Range:

$8.22

$9.055

1-Week Range:

$7.38

$9.055

52-Week Range:

$3.6503

$10.99

Karyopharm Therapeutics Inc Stock (KPTI) Company Profile

Name

Karyopharm Therapeutics Inc

Sector

Healthcare (1111)

Industry

Biotechnology (621)

Phone

617-658-0600

Address

85 WELLS AVENUE, NEWTON, MA

Employee

228

Twitter

@Karyopharm

Next Earnings Date

2026-05-14

Latest SEC Filings

KPTI's Discussions on Twitter

Compare KPTI vs VRTX, REGN, ARGX, ALNY, RVMD

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
KPTI Karyopharm Therapeutics Inc	8.97	184.93M	146.07M	-196.04M	-75.37M	-16.62
VRTX Vertex Pharmaceuticals Inc	435.93	110.28B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	634.62	66.98B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	808.43	50.15B	4.16B	1.29B	734.26M	19.58
ALNY Alnylam Pharmaceuticals Inc	295.50	39.71B	4.29B	577.22M	641.34M	4.2086
RVMD Revolution Medicines Inc	154.89	32.22B	742.00K	-1.37B	-1.07B	-7.0731

Karyopharm Therapeutics Inc Stock (KPTI) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Mar-10-26	Initiated	Rodman & Renshaw	Buy
Feb-05-26	Initiated	Cantor Fitzgerald	Overweight
Oct-13-25	Upgrade	H.C. Wainwright	Neutral → Buy
Jul-16-25	Downgrade	H.C. Wainwright	Buy → Neutral
Jul-11-25	Resumed	H.C. Wainwright	Buy
Jan-19-23	Initiated	Piper Sandler	Overweight
Nov-04-22	Upgrade	RBC Capital Mkts	Sector Perform → Outperform
Feb-09-22	Upgrade	JP Morgan	Underweight → Neutral
Nov-19-21	Resumed	Morgan Stanley	Equal-Weight
Aug-06-21	Downgrade	JP Morgan	Overweight → Neutral
Aug-06-21	Downgrade	RBC Capital Mkts	Outperform → Sector Perform
Aug-06-21	Downgrade	SVB Leerink	Outperform → Mkt Perform
Jul-02-20	Initiated	Morgan Stanley	Overweight
Mar-04-20	Initiated	Barclays	Overweight
Jan-17-20	Downgrade	Wedbush	Outperform → Neutral
Jul-23-19	Upgrade	JP Morgan	Neutral → Overweight
Jul-05-19	Reiterated	H.C. Wainwright	Buy
Jul-05-19	Reiterated	Robert W. Baird	Outperform
Mar-01-19	Downgrade	JP Morgan	Overweight → Neutral
Feb-28-19	Reiterated	BofA/Merrill	Underperform
Feb-27-19	Downgrade	BofA/Merrill	Neutral → Underperform
Jan-03-19	Upgrade	BofA/Merrill	Underperform → Neutral
Dec-03-18	Initiated	B. Riley FBR	Buy
Nov-09-18	Upgrade	Wedbush	Neutral → Outperform
May-24-18	Downgrade	Wedbush	Outperform → Neutral
Apr-02-18	Resumed	Leerink Partners	Outperform
Nov-15-17	Resumed	H.C. Wainwright	Buy
Sep-15-17	Initiated	RBC Capital Mkts	Outperform
Sep-08-16	Reiterated	H.C. Wainwright	Buy
Aug-30-16	Upgrade	Jefferies	Hold → Buy
Aug-18-16	Initiated	H.C. Wainwright	Buy
Jun-28-16	Initiated	Robert W. Baird	Outperform

View All

Karyopharm Therapeutics Inc Stock (KPTI) Latest News

04:17 AM

Karyopharm (KPTI) director Christy Oliger receives 15,508 RSU equity award - Stock Titan

04:17 AM

04:15 AM

Karyopharm (KPTI) director awarded 15,508 RSUs vesting in 2027 - Stock Titan

04:15 AM

04:13 AM

Karyopharm Therapeutics (KPTI) director receives 15,508 RSUs in equity award - Stock Titan

04:13 AM

04:12 AM

Karyopharm (KPTI) director receives 15,508 RSU equity award vesting in 2027 - Stock Titan

04:12 AM

04:06 AM

Karyopharm (NASDAQ: KPTI) director gets 15,508 RSUs vesting in 2027 - Stock Titan

04:06 AM

08:04 AM

Karyopharm Therapeutics Spotlights Selinexor Milestones, ASCO Data and Cancer Trial Readouts - Yahoo Finance

08:04 AM

07:06 AM

Karyopharm Therapeutics Teases ASCO SENTRY Data as FDA Path Comes Into Focus - Yahoo Finance

07:06 AM

May 24, 2026

KPTI PE Ratio & Valuation, Is KPTI Overvalued - Intellectia AI

May 24, 2026

May 22, 2026

KPTI Stock Price, Quote & Chart | KARYOPHARM THERAPEUTICS INC (NASDAQ:KPTI) - ChartMill

May 22, 2026

May 20, 2026

Karyopharm rises on securing $100M in financing to extend cash runway into Q2 2026 - MSN

May 20, 2026

KPTI Technical Analysis | Trend, Signals & Chart Patterns | KARYOPHARM THERAPEUTICS INC (NASDAQ:KPTI) - ChartMill

May 20, 2026

Karyopharm (KPTI) Leans on SENTRY in Pivotal Call - TipRanks

May 20, 2026

Earnings call transcript: Karyopharm Q1 2026 results disappoint, stock drops By Investing.com - Investing.com Australia

May 20, 2026

Earnings call transcript: Karyopharm Q1 2026 results disappoint, stock drops - Investing.com UK

May 20, 2026

May 17, 2026

RBC Capital Remains a Buy on Karyopharm Therapeutics (KPTI) - The Globe and Mail

May 16, 2026

May 15, 2026

Opaleye Management Inc. Reduces Stake in Karyopharm Therapeutics Inc. - GuruFocus

May 15, 2026

Ikarian Capital (KPTI) files joint 13G showing sub‑5% holding - Stock Titan

May 15, 2026

Karyopharm Therapeutics CAO Kristin Abate sells $503 in stock By Investing.com - Investing.com South Africa

May 15, 2026

Karyopharm Therapeutics CAO Kristin Abate sells $503 in stock - Investing.com

May 15, 2026

Karyopharm (KPTI) EVP nets PSUs, then small tax-driven share sale - Stock Titan

May 15, 2026

[Form 4] Karyopharm Therapeutics Inc. Insider Trading Activity - Stock Titan

May 15, 2026

Karyopharm (KPTI) EVP earns PSU shares, sells 324 to cover taxes - Stock Titan

May 15, 2026

Karyopharm (KPTI) CAO reports PSU vesting and small pre-planned tax sale - Stock Titan

May 15, 2026

Karyopharm (KPTI) CEO logs PSU vesting and automatic tax-related share sale - Stock Titan

May 15, 2026

Karyopharm (KPTI) EVP sale covers tax on earned PSU award - Stock Titan

May 15, 2026

Karyopharm (KPTI) Schedule 13G: Acorn entities and Anders Hove report 1.52M shares - Stock Titan

May 15, 2026

RBC Capital Maintains Karyopharm Therapeutics(KPTI.US) With Buy Rating, Maintains Target Price $16 - Moomoo

May 15, 2026

Karyopharm Therapeutics Inc. (NASDAQ:KPTI) Q1 2026 Earnings Call Transcript - Insider Monkey

May 15, 2026

[EFFECT] Karyopharm Therapeutics Inc. SEC Filing - Stock Titan

May 15, 2026

Karyopharm Therapeutics Reports Q1 2026 Results: Full Earnings Call Transcript - Sahm

May 15, 2026

May 14, 2026

Karyopharm Therapeutics 1Q Loss/Shr $1.24 >KPTI - Moomoo

May 14, 2026